

(FILE 'HOME' ENTERED AT 15:59:11 ON 10 FEB 2004)

FILE 'BIOSIS' ENTERED AT 15:59:30 ON 10 FEB 2004

L1 34575 S (INSULIN LIKE GROWTH FACTOR) OR IGF OR (INSULIN
GROWTH FACTOR
L2 42660 S TRANSFORMING GROWTH FACTOR OR TGF
L3 75721 S SPERM OR SEMEN OR SPEMATOZOA OR SEMINAL
L4 3 S L1 AND L2 AND L3
L5 160025 S OOCYTE OR EMBRYO
L6 102 S L1 AND L2 AND L5
L7 31541 S OOCYTE
L8 24 S L7 AND L1 AND L2
L9 21798 S TRANSFERRIN OR TRANSFERIN
L10 139 S L9 AND L3
L11 4580 S SEMINAL PLASMA
L12 51 S L11 AND L9
L13 870539 S CONCENTRATION OR AMOUNT
L14 23 S L13 AND L12
L15 32628 S INOSITOL
L16 21 S L15 AND L11
L17 26562 S FRUCTOSE
L18 5 S L17 AND L16

(FILE 'HOME' ENTERED AT 17:03:20 ON 10 FEB 2004)

FILE 'BIOSIS' ENTERED AT 17:03:32 ON 10 FEB 2004

L1	23639 S INSULIN GROWTH FACTOR OR IGF
L2	4580 S SEMINAL PLASMA
L3	47 S L2 AND L1
L4	870539 S AMOUNT OR CONCENTRATION
L5	10 S L4 AND L3

L Number	Hits	Search Text	DB	Time stamp
1	390	ni-jian.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 10:19
2	66	gentz-reiner.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 10:19
3	192	yu-guo-liang.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 10:19
4	86	dillon-patrick-j.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 10:20
5	1769	chemotactic same cytokine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 10:20
6	209	chemotactic same cytokine same human same polypeptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/02/10 10:21

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal649jxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS	20	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	21	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	22	FEB 05	German (DE) application and patent publication number format changes
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:21:35 ON 10 FEB 2004

=> file medline biosis embase caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 10:21:55 ON 10 FEB 2004

FILE 'BIOSIS' ENTERED AT 10:21:55 ON 10 FEB 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 10:21:55 ON 10 FEB 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 10:21:55 ON 10 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s ni jian /au
L1 557 NI JIAN

=> s gentz reiner /au
L2 192 GENTZ REINER

=> s yu guo-liang
L3 0 YU GUO-LIANG

=> s yu guo-liang /au
L4 204 YU GUO-LIANG

=> s dillon patrick j /au
L5 93 DILLON PATRICK J

=> s chemotactic (s) cytokine (s) polypeptide (s) human
L6 29 CHEMOTACTIC (S) CYTOKINE (S) POLYPEPTIDE (S) HUMAN

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7 25 DUP REM L6 (4 DUPLICATES REMOVED)

=> s (chemotactic (a) cytokine) (s) polypeptide (s) human
L8 12 (CHEMOTACTIC (A) CYTOKINE) (S) POLYPEPTIDE (S) HUMAN

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9 8 DUP REM L8 (4 DUPLICATES REMOVED)

=> d l9 total ibib kwic

L9 ANSWER 1 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
DUPLICATE 1
ACCESSION NUMBER: 2002:423727 BIOSIS
DOCUMENT NUMBER: PREV200200423727
TITLE: Polynucleotides encoding chemokine alpha-3.
AUTHOR(S): Ni, Jian [Inventor]; Li, Haodong [Inventor]; Su, Jeffrey
[Inventor, Reprint author]
CORPORATE SOURCE: Gaithersburg, MD, USA
ASSIGNEE: Human Genome Sciences, Inc.
PATENT INFORMATION: US 6410268 June 25, 2002
SOURCE: Official Gazette of the United States Patent and Trademark

Office Patents, (June 25, 2002) Vol. 1259, No. 4.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 7 Aug 2002
Last Updated on STN: 7 Aug 2002

AB **Human** chemokine Alpha-3 **polypeptides** and DNA (RNA) encoding such **chemotactic cytokines** and a procedure for producing such **polypeptides** by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, . . .

L9 ANSWER 2 OF 8 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:53358 BIOSIS
DOCUMENT NUMBER: PREV200300053358
TITLE: Chemokine alpha 2.
AUTHOR(S): Ni, Jian [Inventor, Reprint Author]; Gentz, Reiner L. [Inventor]; Su, Jeffrey Y. [Inventor]; Li, Haodong [Inventor]
CORPORATE SOURCE: Gaithersburg, MD, USA
ASSIGNEE: Human Genome Sciences, Inc.
PATENT INFORMATION: US 6479633 November 12, 2002
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Nov 12 2002) Vol. 1264, No. 2.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
ISSN: 0098-1133 (ISSN print).

DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Jan 2003
Last Updated on STN: 22 Jan 2003

AB **Human** chemokine Alpha-2 **polypeptides** and DNA (RNA) encoding such **chemotactic cytokines** and a procedure for producing such **polypeptides** by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, . . .

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:640786 CAPLUS
DOCUMENT NUMBER: 127:277253
TITLE: Chemokine alpha 3
INVENTOR(S): Ni, Jian; Li, Haodong; Su, Jeffrey Y.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; Ni, Jian; Li, Haodong; Su, Jeffrey Y.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735027	A1	19970925	WO 1996-US3686	19960318
W: AM, AU, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LT, LV, MD, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2249995	AA	19970925	CA 1996-2249995	19960318
AU 9654254	A1	19971010	AU 1996-54254	19960318
EP 904398	A1	19990331	EP 1996-911336	19960318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000506366	T2	20000530	JP 1997-515324	19960318

PRIORITY APPLN. INFO.:

WO 1996-US3686 A 19960318

AB **Human chemokine $\alpha 3$ polypeptides** and DNA (RNA) encoding such **chemotactic cytokines** and a procedure for producing such **polypeptides** by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, sepsis, wound healing and psoriasis and to stimulate stem cell mobilization. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, ARDS, and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concns. of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:618207 CAPLUS

DOCUMENT NUMBER: 127:261786

TITLE: Chemotactic cytokine III

INVENTOR(S): Ni, Jian; Yu, Guo-Liang; Gentz, Reiner L.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; Ni, Jian; Yu, Guo-Liang; Gentz, Reiner L.

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732993	A1	19970912	WO 1996-US2985	19960305
W:	AM, AT, AU, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LT, LV, MD, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, UG, US, UZ, VN			
RW:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
AU 9655234	A1	19970922	AU 1996-55234	19960305
PRIORITY APPLN. INFO.:			WO 1996-US2985	19960305

AB **Human chemotactic cytokine III**

polypeptides and DNA (RNA) encoding such **chemotactic cytokines** and a procedure for producing such **polypeptides** by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever, cerebral ischemia, glomerulonephritis, HTLV-1 related diseases and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concns. of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding chemotactic cytokine III and for detecting altered levels of the polypeptide in a host.

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:506502 CAPLUS

DOCUMENT NUMBER: 127:108056

TITLE: Human chemotactic cytokine I

INVENTOR(S): Ni, Jian; Yu, Guo-Liang; Alfonso, Pedro; Gentz, Reiner; Su, Jeffrey Y.

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9723640	A1	19970703	WO 1995-US16871	19951226
W: AU, CA, CN, JP, KR, MX, NZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9654143	A1	19970717	AU 1996-54143	19951226
PRIORITY APPLN. INFO.:			WO 1995-US16871	19951226

AB **Human chemotactic cytokine I**
polypeptides and DNA (RNA) encoding such **chemotactic cytokines** and a procedure for producing such **polypeptides** by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, auto-immune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concns. of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptide in a host.

L9 ANSWER 6 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 94002927 EMBASE
 DOCUMENT NUMBER: 1994002927
 TITLE: Production of IL-8 and monocyte chemotactic peptide-1 by peripheral blood monocytes: Disparate responses to phytohemagglutinin and lipopolysaccharide.
 AUTHOR: Liebler J.M.; Kunkel S.L.; Burdick M.D.; Standiford T.J.; Rolfe M.W.; Strieter R.M.
 CORPORATE SOURCE: Pulmonary/Critical Care Med. Div., Oregon Health Sciences University, 3181 S. W. Sam Jackson Park Road, Portland, OR 97201-3098, United States
 SOURCE: Journal of Immunology, (1994) 152/1 (241-249).
 ISSN: 0022-1767 CODEN: JOIMA3
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 005 General Pathology and Pathological Anatomy
 026 Immunology, Serology and Transplantation
 LANGUAGE: English
 SUMMARY LANGUAGE: English

AB . . . a site of inflammation is dependent on a complex interplay of a number of soluble mediators. Recently, two families of **chemotactic cytokines** have been discovered. The -C-X-C- family, which includes IL-8, appears to recruit neutrophils and lymphocytes. In contrast, the -C-C- family, . . . of inflammation, could further amplify the immune response by secreting IL-8 and MCP-1. We sought to define conditions under which **human** peripheral blood monocytes produce IL-8 and MCP-1. Using serum-free media, we found that PHA-stimulated monocytes expressed MCP-1 and IL-8 protein. . . pathways of activation exist for the production of monocyte-derived IL-8 and MCP-1. The differential expression of these different but related **polypeptides** may offer a means of control of the type of immune cells that are recruited to a site of inflammation.

L9 ANSWER 7 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 94073694 EMBASE
DOCUMENT NUMBER: 1994073694
TITLE: Tubular-derived growth factors and cytokines in the
pathogenesis of tubulointerstitial fibrosis: Implications
for human renal disease progression.
AUTHOR: Ong A.C.M.; Fine L.G.
CORPORATE SOURCE: Department of Medicine, Rayne Institute, Univ. College
London Medical School, 5 University St, London WC1E 6JJ,
United Kingdom
SOURCE: American Journal of Kidney Diseases, (1994) 23/2 (205-209).
ISSN: 0272-6386 CODEN: AJKDDP
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
026 Immunology, Serology and Transplantation
028 Urology and Nephrology
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Detailed histomorphometric analysis of **human** biopsy tissue over
the last 30 years has convincingly demonstrated that preservation of the
tubulointerstitial compartment of the kidney is the major determinant of
renal outcome in a variety of **human** renal diseases.
Nevertheless, the pathophysiology of tubulointerstitial disease remains
obscure. In particular, the primary role of tubular injury has not. . .
is now accumulating evidence that apart from their many transport
functions, tubular cells also secrete an array of cytokines, including
chemotactic cytokines, polypeptide growth
factors, and vasoactive peptides. Three paracrine growth systems acting at
different levels in the kidney are described as examples. . . precede
tubular injury, it is tubular injury that sets into motion the
irreversible process of tubulointerstitial fibrosis characteristic of
progressive **human** renal disease, leading to secondary loss of
glomerular function.

L9 ANSWER 8 OF 8 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 92001945 MEDLINE
DOCUMENT NUMBER: 92001945 PubMed ID: 1911703
TITLE: Expression of monocyte chemotactic protein and
interleukin-8 by cytokine-activated human vascular smooth
muscle cells.
AUTHOR: Wang J M; Sica A; Peri G; Walter S; Padura I M; Libby P;
Ceska M; Lindley I; Colotta F; Mantovani A
CORPORATE SOURCE: Istituto di Ricerche Farmacologiche Mario Negri, Milan,
Italy.
SOURCE: ARTERIOSCLEROSIS AND THROMBOSIS, (1991 Sep-Oct) 11 (5)
1166-74.
Journal code: 9101388. ISSN: 1049-8834.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199110
ENTRY DATE: Entered STN: 19920124
Last Updated on STN: 19920124
Entered Medline: 19911025

AB The present study was designed to investigate the capacity of
human vascular smooth muscle cells (SMCs) to produce a
cytokine chemotactic for monocytes (monocyte chemotactic
protein [MCP]) and by way of comparison, a related **polypeptide**
activator of neutrophils (known as interleukin-8 [IL-8] or neutrophil
activating protein-1 [NAP-1]). On exposure to IL-1, SMCs released high

levels. . . .